Business Description
Nautilus Biotechnology Inc
NAICS : 541714
SIC : 2834
ISIN : US63909J1088
Share Class Description:
NAUT: Ordinary SharesTotal Employee Number:
130Description
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.02 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -0.49 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.41 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.3 | |||||
3-Year EPS without NRI Growth Rate | -0.7 | |||||
3-Year FCF Growth Rate | -2.2 | |||||
3-Year Book Growth Rate | -21.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.21 | |||||
9-Day RSI | 32.25 | |||||
14-Day RSI | 29.18 | |||||
3-1 Month Momentum % | -33.46 | |||||
6-1 Month Momentum % | -40.49 | |||||
12-1 Month Momentum % | 141.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.14 | |||||
Quick Ratio | 10.14 | |||||
Cash Ratio | 9.73 | |||||
Days Payable | 24776.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 1.21 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -50 | |||||
Operating Margin % | -627830 | |||||
Net Margin % | -565210 | |||||
EBITDA Margin % | -568160 | |||||
FCF Margin % | -518610 | |||||
OCF Margin % | -502350 | |||||
ROE % | -36.1 | |||||
ROA % | -29.86 | |||||
ROIC % | -77.98 | |||||
3-Year ROIIC % | 4.28 | |||||
ROC (Joel Greenblatt) % | -210.52 | |||||
ROCE % | -34.71 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.85 | |||||
Price-to-Tangible-Book | 0.85 | |||||
EV-to-EBIT | -0.88 | |||||
EV-to-EBITDA | -0.97 | |||||
EV-to-Revenue | 5517.2 | |||||
EV-to-Forward-Revenue | 39.93 | |||||
EV-to-FCF | -1.06 | |||||
| Price-to-Net-Current-Asset-Value | 2.03 | |||||
| Price-to-Net-Cash | 2.13 | |||||
Earnings Yield (Greenblatt) % | -113.64 | |||||
FCF Yield % | -46.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NAUT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nautilus Biotechnology Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.01 | ||
| EPS (TTM) ($) | -0.45 | ||
| Beta | 0.2249 | ||
| 3-Year Sharpe Ratio | -0.11 | ||
| 3-Year Sortino Ratio | -0.18 | ||
| Volatility % | 134.67 | ||
| 14-Day RSI | 29.18 | ||
| 14-Day ATR ($) | 0.096298 | ||
| 20-Day SMA ($) | 0.93794 | ||
| 12-1 Month Momentum % | 141.08 | ||
| 52-Week Range ($) | 0.62 - 4.3101 | ||
| Shares Outstanding (Mil) | 127.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nautilus Biotechnology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nautilus Biotechnology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-28 08:30 | In 65 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 64 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-28 08:30 | 1.66 (-2.92%) | ||
| Second quarter earnings results for 2026 | 2026-07-28 | 1.66 (-2.92%) | ||
| General meeting for 2026 | 2026-06-17 10:00 | 2.17 (-3.56%) | ||
| Alliance Global Partners Annual Virtual Healthcare Conference | 2026-05-20 | 2.38 (+0.85%) | ||
| First quarter earnings conference call for 2026 | 2026-04-28 08:30 | 2.57 (-2.28%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 2.57 (-2.28%) | ||
| Investor Summit Group Virtual Conference` | 2026-03-25 13:00 | 3.95 (+6.47%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 10:30 | 2.42 (+0.00%) |
Show
Entries
Nautilus Biotechnology Inc Frequently Asked Questions
What is Nautilus Biotechnology Inc(NAUT)'s stock price today?
The current price of NAUT is $0.87. The 52 week high of NAUT is $4.31 and 52 week low is $0.62.
When is next earnings date of Nautilus Biotechnology Inc(NAUT)?
The next earnings date of Nautilus Biotechnology Inc(NAUT) is 2026-10-28 Est..
Does Nautilus Biotechnology Inc(NAUT) pay dividends? If so, how much?
Nautilus Biotechnology Inc(NAUT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nautilus Biotechnology Inc
Nautilus Biotechnology Inc (NAUT) Q2 2026 Earnings Call Highlights: Strategic Shifts and Financial Outlook
Jul 28, 2026
Is Nautilus Biotechnology Inc (NAUT) Positioned to Succeed After Q2 Earnings Miss? GF Score: 22/100, EPS: -$0.11
Jul 28, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers